Neoadjuvant oxaliplatin-based chemotherapy for liver metastases from colorectal cancer. An Italian survey

Alberto Zaniboni, Valter Torri, Angelo Tinazzi, Claudio Codignola, Roberto Faggiuolo, Elisa Sperti

Research output: Contribution to journalArticlepeer-review


Background: Only 10% to 25% of patients with liver metastases from colorectal cancer are suitable for resection. Methods for increasing the resectability of liver metastases are based on specific surgical techniques and neoadjuvant chemotherapy. Methods: We collected retrospective data on patients from various Italian hospitals from 1996 to 2002. Data from colorectal cancer patients with liver metastases treated with oxaliplatin-based neoadjuvant chemotherapy were considered. Analysis focused on patients and treatment description and on long-term survival. We considered 107 patients from 36 Italian hospitals. Results: Of the 105 patients assessable for response, 8.4% achieved a complete response, 70.1% a partial response and 19.6% stable disease. Ninety-nine patients were treated with surgery for liver metastases. A radical resection was achieved in 79% of patients. Median survival time was 42 months. Thirteen patients experienced grade 3-4 hematologic toxicity, and 10 patients had grade 3-4 nonhematologic toxicity. Neurologic toxicity of grade > 1 was observed in 21% of patients. Conclusions: Neoadjuvant chemotherapy can be useful to increase the number of liver resections for metastatic colorectal cancer patients. Nevertheless, randomized trials are necessary to confirm this retrospective survey as well as the few single-institution experiences reported so far in the medical literature.

Original languageEnglish
Pages (from-to)383-387
Number of pages5
Issue number5
Publication statusPublished - Sep 2005


  • Colorectal cancer
  • Liver metastases
  • Neoadjuvant chemotherapy
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Neoadjuvant oxaliplatin-based chemotherapy for liver metastases from colorectal cancer. An Italian survey'. Together they form a unique fingerprint.

Cite this